A clear mechanistic interaction between PYK2 and IRF5, in macrophages, identified in this study, combined with an acceptable toxicological profile of PYK2 inhibitor defactinib shown in cancer clinical trials50, deserves a closer look from the therapeutic perspective. Here, IRF5 is linked to cancer.